Tolerance induction by third-party “off-the-shelf” CD4 +CD25 + Treg cells

Recent reports have shown that donor or host CD4 +CD25 + Treg cells can be used to control GVHD or graft rejection following allogeneic BMT in mice. In the present study we investigated the potential of third-party Treg cells compared to donor-type cells to facilitate BM allografting. Graft rejectio...

Full description

Saved in:
Bibliographic Details
Published in:Experimental hematology 2006, Vol.34 (1), p.66-71
Main Authors: Steiner, David, Brunicki, Noga, Blazar, Bruce R., Bachar-Lustig, Esther, Reisner, Yair
Format: Article
Language:English
Subjects:
Animals
Bone Marrow Transplantation - adverse effects
Cell Survival - drug effects
Disease Models, Animal
Female
Graft Rejection - immunology
Graft vs Host Disease - immunology
In Vitro Techniques
Injections, Intravenous
Mice
Mice, Inbred BALB C
Mice, Inbred C3H
Mice, Inbred C57BL
Mice, Nude
Sirolimus - administration & dosage
T-Lymphocytes, Regulatory - drug effects
T-Lymphocytes, Regulatory - immunology
T-Lymphocytes, Regulatory - radiation effects
Transplantation Chimera
Transplantation Immunology - immunology
Transplantation Tolerance - drug effects
Transplantation Tolerance - radiation effects
Transplantation, Homologous - adverse effects
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Recent reports have shown that donor or host CD4 +CD25 + Treg cells can be used to control GVHD or graft rejection following allogeneic BMT in mice. In the present study we investigated the potential of third-party Treg cells compared to donor-type cells to facilitate BM allografting. Graft rejection is assessed in a mouse model of T cell–mediated BM allograft rejection. Lethally irradiated C3H mice are transplanted at day 2 after irradiation with T cell–depleted Balb/Nude BM. Graft rejection is induced by purified host-type T cells infused one day prior to BMT. Cells tested for their facilitating activity are added to the T cell–depleted BM allograft. Naïve or ex vivo–expanded third-party Treg cells can effectively enhance engraftment of T cell–depleted BM allografts, exhibiting reactivity in vitro and in vivo similar to that found for donor-type Treg cells. The use of third-party Treg cells in contrast to donor-type cells could allow advanced preparation of a large bank of Treg cells (off-the-shelf), with all the appropriate quality controls required for cell therapy.
ISSN:0301-472X
1873-2399
DOI:10.1016/j.exphem.2005.10.011